D
Dominique Becquart
Publications - 4
Citations - 1713
Dominique Becquart is an academic researcher. The author has contributed to research in topics: Letrozole & Tamoxifen. The author has an hindex of 2, co-authored 4 publications receiving 1670 citations.
Papers
More filters
Journal ArticleDOI
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jänicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,Mercedes Lassus,J. Arnold Verbeek,Beatrix Staffler,H. A. Chaudri-Ross,Margaret Dugan +20 more
TL;DR: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate, and its results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Journal ArticleDOI
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jaenicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,H. A. Chaudri-Ross,Raquel Lang,Peter J. Wyld,Ajay Bhatnagar +19 more
TL;DR: This study documents the superiority of letrozole over tamoxifen in first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Superior E fficacy o f L etrozole V ersus T amoxifen a s First-Line T herapy f or P ostmenopausal W omen W ith Advanced B reast C ancer: R esults o f a P hase I II S tudy o f the I nternational L etrozole B reast C ancer G roup
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,Mercedes Lassus,J. Arnold Verbeek,Beatrix Staffler,H. A. Chaudri-Ross,Margaret Dugan +18 more
TL;DR: In this paper, the authors compared the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamioxifen as first-line therapy in postmenopausal women with advanced breast cancer.
Phase I II S tudy o f L etrozole V ersus T amoxifen a s F irst-Line Therapy o f A dvanced B reast C ancer i n P ostmenopausal Women: A nalysis o f S urvival a nd U pdate o f E fficacy F rom t he International L etrozole B reast C ancer G roup
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jaenicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,H. A. Chaudri-Ross,Raquel Lang,Peter J. Wyld,Ajay Bhatnagar +18 more
TL;DR: In this article, the superiority of letrozole versus tamoxifen was confirmed for time to progression (median, 9.4 v 6.0 months, respectively; P <.0001), time to treatment failure, overall objective response rate (32% v 21%, respectively, P.0002), and overall clinical benefit.